Physician profile
Valley C Dreisbach
NPI 1629250527
$1,144.19
in general payments reported to CMS, 2019-2025
14 companies · $16.88 in 2025
The $16.88 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $227 · 2021: $11.92 · 2022: $59.10 · 2025: $16.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.83 | 2019-2022 | |
| Janssen Biotech, INC. | $170.64 | 2019-2020 | |
| Allergan, INC. | $143.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $98.36 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.08 | 2019 | |
| Pfizer INC. | $57.93 | 2019-2020 | |
| Ucb, INC. | $35.43 | 2019 | |
| Shionogi INC | $32.86 | 2019 | |
| Shire North American Group INC | $21.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.52 | 2019 | |
| Gilead Sciences, INC. | $17.89 | 2019 | |
| Novo Nordisk INC | $16.88 | 2025 | Wegovy |
| Amag Pharmaceuticals, INC. | $15.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valley Dreisbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.